case_images: PMC11405209_01
case_images: Flow chart of the disease process and therapeutic modalities. DEL, double-expressor diffuse large B-cell lymphoma. R-CDOP, rituximab, cyclophosphamide, liposomal doxorubicin, vincristine, and prednisone. methotrexate, methotrexate. BRT, bridging radiotherapy. FC, fludarabine and cyclophosphamide. PR, partial response. CR, complete response. R-CDOP*2, two cycles of R-CDOP treatment. R-MTX-Lenalidomide*1, one cycle of R-MTX-Lenalidomide treatment. R-MTX-Orelabrutinib*1, one cycle of R-MTX-Orelabrutinib treatment. DHAP*1, one cycle of DHAP treatment. R-MTX-Orelabrutinib-Lenalidomide*4, four cycle of R-MTX-Orelabrutinib-Lenalidomide treatment. MTX*1, one cycle of MTX treatment.
case_images: fimmu-15-1441404-g001.jpg
case_images: PMC11405209_01_fimmu-15-1441404-g001.jpg
case_images: f1
case_images: Subsequent treatment included regimens incorporating rituximab, methotrexate, lenalidomide, and orelabrutinib ( Figure 1 ).
case_images: PMC11405209_02
case_images: PET-CT scan before bridging radiotherapy (9 Feb 2023) (A), bridging radiotherapy treatment (20 Feb 2023) (B) and after bridging radiotherapy treatment (3 Mar 2023) (C). The patient remains in CR with CAR-T therapy to date (D-G). bridging radiotherapy, bridging radiotherapy. GTV, gross tumor volume. CTV, clinical tumor volume. PTV, planning target volume. The red line represents GTV, the yellow line represents CTV, and the green line represents PTV.
case_images: fimmu-15-1441404-g002.jpg
case_images: PMC11405209_03_fimmu-15-1441404-g002.jpg
case_images: f2
case_images: The patient remained complete response for more than 9 months after anti-CD19 CAR-T reinfusion ( Figures 2D-G ).
case_images: PMC11405209_03
case_images: PET-CT scan before bridging radiotherapy (9 Feb 2023) (A), bridging radiotherapy treatment (20 Feb 2023) (B) and after bridging radiotherapy treatment (3 Mar 2023) (C). The patient remains in CR with CAR-T therapy to date (D-G). bridging radiotherapy, bridging radiotherapy. GTV, gross tumor volume. CTV, clinical tumor volume. PTV, planning target volume. The red line represents GTV, the yellow line represents CTV, and the green line represents PTV.
case_images: fimmu-15-1441404-g002.jpg
case_images: PMC11405209_03_fimmu-15-1441404-g002.jpg
case_images: f2
case_images: The patient remained complete response for more than 9 months after anti-CD19 CAR-T reinfusion ( Figures 2D-G ).